Antiemetic, prokinetic medication.

Antagonises dopamine D2 receptor which causes

  1. peripheral (increased oesophageal and gut motility, lowered oesophageal sphincter pressure, increased gastric emptying) and 
  2. central (block of chemoreceptor trigger zone (CTZ) in medulla) effects.

Indications and dose


Onset of action

  • Intravenous: 1–3 minutes
  • Intramuscular: 10–15 minutes
  • Peroral: 30–60 minutes

Duration of action: 1–2 hours

Half-life of elimination: 5–6 hours

Metabolism: Hepatic

Elimination: Kidneys

Directions for administration

Metoclopramide should be used for a maximum of 5 days.

Intravenous dose should be administered as a slow bolus over at least 3 minutes. 

Reduce dose by 50 % in patients with moderate to severe renal impairment (creatinine clearance 15–60 ml/min) or severe hepatic impairment.

Reduce dose by 75 % in patients with end stage renal disease (creatinine clearance <15 ml/min)

Medicinal forms

Tablets – 10 mg

Solution for injection – 5 mg/ml 

  • 1 vial = 2 ml (10 mg), 10 ml (50 mg)


CNS: restlessness, drowsiness, insomnia, anxiety, agitation

Extrapyramidal effects: acute dystonia, tardive dyskinesia, parkinsonian features (high risk at higher doses and long-term therapy)


  1. Pharm 101: Metoclopramide • LITFL
  2. Metoclopramide: Uses, Interactions, Mechanism of Action | DrugBank Online
  3. label (